In this phase @b trial , we randomly assigned @ patients with newly diagnosed , smear-positive , multidrug-resistant tuberculosis to receive either @ mg of bedaquiline once daily for @ weeks , followed by @ mg three times a week for @ weeks , or placebo , both in combination with a preferred background regimen .